新诊断中危局限性前列腺癌中[68Ga]Ga-RM2与[68Ga]Ga-PSMA-617 PET/CT的前瞻性头对头比较
该前瞻性研究纳入22例活检证实的中危前列腺癌初治患者,在根治性前列腺切除术前分别行[68Ga]Ga-PSMA-617和[68Ga]Ga-RM2 PET/CT,以组织学为参照。结果显示ISUP≤2病灶中RM2的SUVmax显著高于PSMA-617,而ISUP≥3病灶中PSMA-617的SUVmax显著高于ISUP≤2病灶。提示联合PSMA与GRPR显像有助于区分ISUP 2与ISUP 3前列腺癌,为治疗决策提供信息。
要点
- ISUP≤2病灶中[68Ga]Ga-RM2 SUVmax显著高于[68Ga]Ga-PSMA-617(p=0.027)。
- ISUP≥3病灶中[68Ga]Ga-PSMA-617 SUVmax显著高于ISUP≤2病灶(p=0.001)。
- 联合PSMA与GRPR显像可区分ISUP 2与ISUP 3前列腺癌。
核心结论
- 联合PSMA显像与GRPR显像能够区分ISUP 2与ISUP 3前列腺癌,为治疗决策提供有价值的信息。
研究设计与样本
- 前瞻性头对头比较研究,纳入22例活检证实、未接受过治疗且为根治性前列腺切除候选者的中危前列腺癌患者。
- 患者分别接受[68Ga]Ga-PSMA-617(放射性标记PSMA抑制剂)与[68Ga]Ga-RM2(放射性标记GRPR拮抗剂)PET/CT显像,以组织学为参照。
- 18例患者有磁共振成像(MRI)资料。
- 试验注册号NCT03606837,于2019年7月11日前瞻性注册。
主要发现
- 在ISUP≤2病灶中,[68Ga]Ga-RM2的SUVmax显著高于[68Ga]Ga-PSMA-617的SUVmax(p=0.027)。
- 在ISUP≥3病灶中,[68Ga]Ga-PSMA-617的SUVmax显著高于ISUP≤2病灶(p=0.001)。
关键数值与推荐
- 中危前列腺癌可依据ISUP评分分为有利型(ISUP 2)与不利型(ISUP 3)。
- GRPR在低危前列腺癌(低ISUP评分、低PSA、小肿瘤体积)中过表达。
- PSMA靶向PET/CT推荐用于高危前列腺癌评估。
临床怎么用
- 对中危前列腺癌患者,可考虑联合PSMA与GRPR靶向PET/CT显像,辅助区分ISUP 2与ISUP 3以支持治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Intermediate-risk (IR) prostatic adenocarcinoma is an heterogeneous subgroup of prostate cancer with discrepant progression and prognosis. These tumors can be subclassified based on the ISUP (International Society of Urology Pathology) score into favorable (ISUP 2) and unfavorable (ISUP 3) IR prostate cancer. Positron Emission Tomography / Computed Tomography (PET/CT) imaging targeting PSMA (Prostate Specific Membrane Antigen) is recommended for the assessment of high-risk prostate cancers. On the other hand, GRPR (Gastrin-Releasing Peptide Receptor) is over-expressed in low-risk prostate cancers (low ISUP score, low PSA and small tumor size). The aim of this study is to evaluate the relevance of PSMA- and GRPR-targeted PET/CT imaging for primary tumor stratification in newly diagnosed intermediate-risk patients. METHODS: 22 patients with biopsy-confirmed intermediate-risk prostate cancer with no prior treatment and candidates for radical prostatectomy were imaged with [68Ga]Ga-PSMA-617 (a radiolabeled PSMA-inhibitor) and [68Ga]Ga-RM2 (a radiolabeled GRPR antagonist). Histology served as reference. Magnetic Resonance Imaging (MRI) was available in 18 patients. RESULTS: [68Ga]Ga-RM2 SUVmax was significantly higher than [68Ga]Ga-PSMA-617 SUVmax in ISUP ≤ 2 lesions (p = 0.027). [68Ga]Ga-PSMA-617 SUVmax was significantly higher in ISUP ≥ 3 lesions than ISUP ≤ 2 lesions (p = 0.001) CONCLUSION: These results suggest that the combined use of PSMA imaging and GRPR imaging is able to discriminate ISUP 2 from ISUP 3 prostate cancer and thus provides valuable information for treatment decision making. TRIAL REGISTRATION NUMBER: NCT03606837 (prospectively registered on 11/07/2019).
引用
- Perozziello F, Robert G, Meyer M, et al. Prospective head-to-head comparison of [68Ga]Ga-RM2 PET/CT and [68Ga]Ga-PSMA-617 PET/CT in newly diagnosed patients with intermediate-risk localized prostate cancer. Eur J Nucl Med Mol Imaging. 2026. PMID: 41656418. doi:10.1007/s00259-026-07780-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。